Evaluation of Epithelial-Mesenchymal Transition Genes Involved in Iranian Gastric Cancer Patients via Transcriptome Analysis

Shima Abed 1, Kaveh Baghaei 2, Parviz Pakzad 3, Mehrdad Hashemi 4 and Mohammad Reza Zali 5, *

1Department of Biology, Faculty of Biological Sciences, North Tehran Branch, Islamic Azad University, Tehran, Iran
2Basic and Molecular Epidemiology of Gastrointestinal Disorder Research Center, Research Institute for Gastroenterology and Liver Disease, Shahid Beheshti University of Medical Science, Tehran, Iran
3Department of Microbiology, Faculty of Basic Sciences, North Tehran Branch, Islamic Azad University, Tehran, Iran
4Department of Genetics, Tehran Medical Sciences Branch, Islamic Azad University, Tehran, Iran
5Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran

*Corresponding author: Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Email: mnzali@hotmail.com

Received 2019 June 04; Revised 2019 September 25; Accepted 2019 September 29.

Abstract

Background: Gastric cancer is one of the most frequent cancers among men and women. Patients with gastric cancer are mostly diagnosed in advanced stages because of asymptomatic progression. Due to the heterogeneity and poor prognosis of this cancer, a comprehensive study at the transcriptome level gene expression is needed to find the various genes and mechanisms involved in gastric cancer. Differentially expressed genes (DEG) derived from high-throughput RNA-sequencing could lead to the achievement of new molecular biomarkers.

Objectives: In this study, after transcriptome reanalysis, we focused on the genes involved in epithelial-mesenchymal transition (EMT) via extracellular matrix (ECM). We have aimed at finding mRNA level changes in new candidate genes among Iranian patients with gastric cancer.

Methods: Six gastric cancer and two normal sequencing raw sample datasets were collected from the European Nucleotide Archive (ENA). The bioinformatic pipeline was used to reanalyze raw datasets and get DEGs, using the DESeq2 package. After analyzing, THBS2, OSMR, and CHI3L1 genes were selected for validation and verification in 25 confirmed adenocarcinoma gastric cancer patients and non-malignant normal tissues from the Iranian population by real-time polymerase chain reaction (PCR).

Results: The bioinformatic analysis of raw datasets revealed many upregulated and downregulated genes in gastric cancer tissues compared with normal samples. Then, real-time PCR verified the upregulation of THBS2, OSMR, and CHI3L1 genes in a group of Iranian patients with gastric cancer. Analyzing graphs showed a significant increase in the expression of targeted genes in patients with gastric cancer (P < 0.0001, P = 0.0016, and P = 0.0002, respectively).

Conclusions: The results validated an obvious increase in the expression of THBS2, OSMR, and CHI3L1 genes in gastric cancer of Iranian patients. These genes are involved in EMT and may have a role in cancer invasion if tested further for their diagnostic and prognostic value in larger sample sizes.

Keywords: Gastric Cancer, Bioinformatic Pipeline, Differentially Expressed Genes, Epithelial-Mesenchymal Transition, Extracellular Matrix

1. Background

Gastric cancer is one of the leading causes of cancer death worldwide. The incidence and mortality of this cancer are higher in the Asian population compared with other nations. The highest incidence in Asia has been reported from some countries, such as China and Korea and the survival rate is about 5 years (1, 2). Gastric cancer is classified into two subgroups including intestinal and diffuse types according to Lauren classification. Furthermore, recently another molecular classification divided gastric cancer into 4 subgroups characterized by the existence of Helicobacter pylori or Epstein-Barr virus (EBV), microsatellite instability (MSI), mutations related to gastric cancer, and transcriptional or epigenetic changes (3, 4). In spite of the aforementioned classifications, gastric cancer’s poor prognosis is still challenging and complementary methods are needed for the early diagnosis. In addition to the timely diagnosis of cancer, the invasive and metastatic
state of gastric cancer is one of the problems that can increase the mortality rate of this type of cancer.

One of the mechanisms involved in the formation of metastasis and the creation of an aggressive state in cancer is an epithelial-mesenchymal transition (EMT) process. EMT is a highly-regulated process in embryogenesis and wound healing. In cancer, cells progressively lose their epithelial features while gaining mesenchymal markers that lead to cellular detachment from the primary tumor, which leads to metastasis and invasion of cancer. The extracellular matrix (ECM) is a key component of a cell’s microenvironment that could induce EMT in cancer cells by activating different signaling cascades. The aberrant regulation of signaling pathways may lead to the EMT activation of gastric cells, which allows tumor cells to spread throughout the body (5, 6).

In the last decades, high-throughput next generation sequencing (NGS) technologies have replaced the traditional methods for identifying novel molecular biomarkers and alteration of gene expression. Several large-scale studies have identified the various genes involved in the EMT process (3, 7).

One of the targeted genes in the current study was thrombospondin 2 (THBS2), which is the second member of the thrombospondin family that can mediate ECM interactions by interacting with multiple cell receptors and other proteins (8). Adherence ability to ECM is important for cancer cell migration and invasion. Furthermore, this glycoprotein, which is secreted by various types of cells, including stromal fibroblasts, endothelial, and immune cells, could promote EMT by activating different cascades such as TGF-β and PI3K pathways (6, 9). The overexpression of THBS2 was observed in the bladder, CNS, breast, colorectal, pancreatic, lung, and gastric cancers and correlated with poor prognosis (10).

Another targeted gene in this study was the oncostatin M receptor (OSMR), which is a member of the interleukin 6 (IL6) receptor family. This receptor binds to gp130 to form the receptor for its main ligand, multifunctional cytokine oncostatin M (OSM) (11). Also, it can bind to IL31, which is one of the inflammatory cytokines. OSMR is expressed in many types of cells including leukocytes, endothelial cells, hepatocytes, neurons, and some epithelial cells. The overexpression of this cytokine and its receptor was reported in many tumor cell types. OSM-OSMR could induce the EMT process mainly through the JAK/STAT pathway (12).

Chitinase-3-like protein 1 (CHI3L1) or cartilage glycoprotein-39, also known as YKL-40, was the last gene that was validated in the current experiment. This glycoprotein is a 40 kDa carbohydrate-binding lectin and it has no chitinase activity. Normally, CHI3L1 is a growth factor for connective tissue cells, but the exact biological function of this protein in cancer is largely unknown. The upregulation of this gene was reported in many inflammatory conditions and inflammatory cytokines like IL6, IL13, and TNF-alpha could regulate its expression (13). It is believed that YKL-40 interacts with many components of ECM like collagens and fibronectin. The upregulation of this gene might induce EMT through JAK/STAT signaling pathway (14).

Given the role of genes involved in EMT and subsequent malignancy in gastric cancer, we have carried out a bioinformatics analysis on the raw data that were collected from RNA-seq published in the study. At the end of the analysis, we have reached a vast variety of genes that were differentially expressed in both up- and downregulation in gastric cancer tissues compared with normal samples. Then, we have selected those genes, which were involved in the EMT procedure from the top 10 significantly upregulated candidates for validating their role in the malignancy of gastric cancer in the Iranian population.

2. Methods

2.1. Bioinformatic Analysis

Six gastric cancer (including three tissues and three cell lines) and two normal sequencing raw sample datasets were collected from the European Nucleotide Archive (ENA) (ENA; SRX93413) (https://www.ebi.ac.uk/ena/data/view/SRR585570-SRR585577). These paired datasets were generated, using Illumina Genome Analyzer II and were downloaded in the form of FASTQ files. All raw reads were qualified by FastQC software and, then, were trimmed by Trimomatic (version 0.36) tool, which was developed to remove adapters and scan every read and trim the lower-scored bases. After quality control and trimming, the clean reads were aligned to the human reference genome (GRCh38.92), using Hisat2 (version 2.1.0) software. The output of the previous step was stored in the form of the SAM file and was used as an input for obtaining raw counts by HTSeq software. Finally, in order to get DEGs, the analysis was performed, using the R software and DESeq2 package (Bioconductor package).

Pathway enrichment analysis has been performed for all upregulated and downregulated genes, using the Enrichr database (Enrichr; http://amp.pharm.mssm.edu/Enrichr/). Then, 3 genes from upregulated DEGs were selected for validating in the Iranian population and protein-protein interactions (PPI) have been used by the STRING database (STRING; https://string-db.org/).
2.2. Tissue Samples

In this case-control study, 25 confirmed adenocarcinoma gastric cancer and non-malignant normal tissues according to their pathology reports (Table 1) were recruited within 2 years from Taleghani Educational Hospital and Imam Hossein Educational Hospital, Tehran, Iran. The participants of this study have not received any treatment like chemotherapy, radiotherapy, and immune therapy. Written consent was obtained from each individual. Specimens were stored in RNA later stabilizing solution (QIAGEN) at -70°C.

Table 1. Features of Samples

| Features                  | Frequency (%) |
|---------------------------|---------------|
| Age                       |               |
| > 50                      | 21 (84)       |
| \( \leq 50 \)             | 4 (16)        |
| Sex                       |               |
| Female                    | 5 (20)        |
| Male                      | 20 (80)       |
| Gastric cancer type       |               |
| Adenocarcinoma, moderate to poorly differentiated | 15 (60) |
| Adenocarcinoma, differentiated | 10 (40) |

* Samples were from 25 patients with gastric cancer.

2.3. RNA Extraction and cDNA Synthesis

Total RNA was extracted by QIAGEN All Prep DNA/RNA/miRNA Universal Kit (Cat. No.: 80224) from 30 mg of fresh tissue. The tissue was grinded in liquid nitrogen by mortar and pestle and the rest of the process was carried out according to protocol step by step. Finally, the quality of RNAs was checked by measuring the optical density with the Nanodrop (Thermo Fisher Scientific, USA) to confirm that the ratio of the absorbance at 260 nm and 280 nm ranging from 1.8 to 2.0. cDNA was synthesized by Thermo Fisher Revert Aid First Strand cDNA Synthesis Kit, using Random Hexamer primers (Cat. No.: k1691).

2.4. Real-Time Polymerase Chain Reaction (PCR)

To confirm the targeted genes with real-time PCR, their expression levels were measured. The reaction was carried out in a total volume of 25 µL, which included 12.5 µL of Amplicon SYBR Green without ROX (Cat. No.: A323402). PCR was performed at 95°C for 15 minutes in order to activate the Hot start Taq DNA polymerase and, then, for 40 cycles of amplification at 95°C for the 30 seconds appropriate annealing temperature for each gene and 60 seconds in a two-step program on a Rotor-Gene Q real-time PCR machine. All samples were tested in duplicate, and samples without template were included in each PCR plate as a negative control. The levels of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA were quantified in each sample, and the expression level of each sample was calculated as the value of targeted mRNAs divided by that of GAPDH mRNA. The amplified fluorescence signal in each specimen was measured at the late extension step of each cycle. All primers were designed by Primer 3 software and the accuracy and specificity of the primers were evaluated by the Gene Runner tool (version 6.0.04). Finally, primers were blasted at NCBI. The following sequence of primers was used: 5'-ACTTCAGGGGTGGCTTCCAG-3' (forward) and 5'-GTGTCCTCAGTGCCGTG-3' (reverse) for THBS2, 5'-CGTTTACCATTAGACTCCTTG-3' (forward) and 5'- AATTCGCCACCAGCATGAC-3' (reverse) for OSMR, 5'- CTCAGAACGGAACCCC-3' (forward) and 5'- TCCAGGCACTAAAGC -3' (reverse) for CHI3L1, 5'-AATCCTCCATACCTTTC-3' (forward) and 5'-TGGAATCCAGCACGTACT-3' (reverse) for GAPDH.

2.5. Statistical Analyses

The analysis was performed, using the R package (DESeq2). Normalization and differential analysis are carried out according to the DESeq2 model (P < 0.05). The validation of real-time PCR datasets was analyzed, using REST 2009 (version 2.0.13) and Prism5 software. All data are presented as the mean ± SEM and expression ratio was analyzed, using the two-tailed, unpaired t-test (P < 0.05).

3. Results

In this study, we have carried out the bioinformatic analysis of raw data that was collected from the RNA-seq published experiment; 3762 genes were differentially expressed between normal and affected tissues (P_{adj} value < 0.05), including 1393 upregulated and 2369 downregulated (Figure 1).

To better understand, the biological pathways of all upregulated and downregulated genes were considered, using the Enrichr online database (Reactome 2016) (Tables 2 and 3). The downregulation of different immune-related pathways was observed in gastric cancer tissues (Table 2) (P < 0.05). Here, we have focused on upregulated genes. Reactome pathway enrichment analysis has demonstrated the upregulation of ECM interactions and changing in ECM structure, which is the main step in the EMT process (Table 2).

We have selected 3 genes involving in ECM, including THBS2, OSMR, and CHI3L1 from the top 10 upregulated genes (Table 4) (P_{adj} value < XE-11 and log2 fold change > 2).
Figure 1. MA-plot and Volcano plot of each comparison. Red dots represent significantly differentially expressed features between normal and affected (primary) tissues. MA-plot (left) represents the log ratio of differential expression as a function of the mean intensity for each feature and Volcano plot (right) represents the log of the adjusted P value as a function of the log ratio of differential expression.

Table 2. Reactome Pathways That Were Significantly Upregulated in Gastric Cancer

| Pathways                                                                 | PValue   |
|--------------------------------------------------------------------------|----------|
| Crosslinking of collagen fibrils-Homo sapiens, R-HSA-2243919              | 0.002204 |
| Extracellular matrix organization-Homo sapiens, R-HSA-1474244             | 0.004527 |
| Laminin interactions-Homo sapiens, R-HSA-3000057                          | 0.004028 |
| Non-integrin membrane-ECM interactions-Homo sapiens, R-HSA-3000071        | 0.007538 |
| Interleukin-6 family signaling-Homo sapiens, R-HSA-6783589                | 0.009309 |
| Fibronectin matrix formation-Homo sapiens, R-HSA-1566977                  | 0.005712 |
| Assembly of collagen fibrils and other multimeric structures-Homo sapiens, R-HSA-2022090 | 0.0147   |
| Purine ribonucleoside monophosphate biosynthesis-Homo sapiens, R-HSA-73817 | 0.007317 |
| Collagen formation_Homo sapiens, R-HSA-1474290                           | 0.01427  |
| II-6-type cytokine receptor ligand interactions_Homo sapiens, R-HSA-6788467 | 0.03036  |

Based on PPI information from the STRING database, we have evaluated the interaction of these proteins (Figure 2). Proteins in this network are involved in two regulatory signaling pathways, including JAK/STAT and PI3K/AKT (KEGG pathway ID: 04630 and 04151, respectively). Both pathways have been considered to activate by ECM interactions.

Real-time PCR verified the upregulation of THBS2, OSMR, and CHI3L1 (P < 0.05) in 25 gastric cancer tissues compared with noncancerous tissues (Figures 3 and 4).

4. Discussion

Although important progress has been made to identify the biological and molecular mechanisms of gastric cancer, the heterogeneity and poor prognosis of gastric cancer are still challenging.

In the current study, we have collected DEGs in gastric cancer, using the bioinformatics pipeline. The results of the present study have indicated that most of the genes that were significantly upregulated in gastric cancer tissues have a role in ECM interactions. We have aimed at selecting genes that have a role in the EMT process by making changes in the ECM environment. Although EMT is a complex process in metastasis initiation in cancer cells, changing in ECM organization including collagen, laminin, and fibronectin formation have been observed in our analysis (Table 2). We have assumed that the overlapping of different intracellular cascades activated by the upregulation of ECM interactions leads to EMT in cancer cells.

4 Int J Cancer Manag. 2019; 12(12):e94924.
Table 3. Reactome Pathways That Were Significantly Downregulated in Gastric Cancer

| Pathways                                                                 | P Value    |
|---------------------------------------------------------------------------|------------|
| Immunoregulatory interactions between a lymphoid and a non-lymphoid cell | 1.467e-17  |
| FCGR activation _Homo sapiens_ R-HSA-2029481                               | 2.928e-13  |
| Role of phospholipids in phagocytosis _Homo sapiens_ R-HSA-2029485         | 1.395e-10  |
| Classical antibody-mediated complement activation _Homo sapiens_ R-HSA-173623 | 3.213e-10  |
| Initial triggering of complement _Homo sapiens_ R-HSA-166663              | 3.393e-10  |
| Complement cascade _Homo sapiens_ R-HSA-166658                             | 1.239e-10  |
| Creation of C4 and C2 activators _Homo sapiens_ R-HSA-166786              | 1.150e-9   |
| Scavenging of heme from plasma _Homo sapiens_ R-HSA-2168880               | 1.689e-9   |
| FCERI mediated Ca²⁺ mobilization _Homo sapiens_ R-HSA-2871809              | 5.369e-8   |
| Binding and Uptake of Ligands by Scavenger Receptors _Homo sapiens_ R-HSA-2173782 | 3.514e-8   |

Figure 2. PPI network among THBS2, OSMR and CH3L1 proteins (https://string-db.org/). The red nodes represent proteins in PI3K/AKT pathway and the blue nodes represent proteins in JAK/STAT pathway.

THBS2 was one of the targeted genes that have a role in ECM interactions. Previously, Wang et al., have considered THBS2 a novel prognostic marker in colorectal cancer detection. They have verified the role of this glycoprotein in the focal adhesion, ECM interactions, and TGF-β signaling pathway. Also, they have demonstrated the correlation between THBS2 and EMT markers in their comprehensive meta-analysis study (8). Sun et al. have reported that most cases with gastric cancer showed a lower level of THBS2 in comparison with normal cases in 14 Chinese patients (15). In contrast with the previous study, in another experiment in China with a larger sample size including 105 patients, the relationship between the expression of THBS2, COLIA2, and SPP1 genes, as well as gastric cancer
incidence, was investigated (16). Their results have shown the upregulation of THBS2, but not COL1A2 and SPP1 in gastric cancer tissues. In line with the previous study, Kim et al. have reported THBS2/CA19-9 as a new biomarker in the early detection of pancreatic ductal adenocarcinoma. They have found out that the concentration of THBS2 in plasma could discriminate patients with pancreatic ductal adenocarcinoma from healthy controls with high specificity but not significant sensitivity (17). According to their results, combining THBS2 with CA19 has increased sensitivity up to 87%. Furthermore, in another meta-analysis study by Jiang et al., the upregulation of the THBS2 gene was confirmed in gastric cancer from an integrative analysis of gene expression dataset (18). As our expectations and inconsistent with most studies, we have validated the upregulation of this gene in the Iranian group of patients including 25 patients with confirmed gastric adenocarcinoma by real-time PCR (P < 0.0001). This glycoprotein may play its role through the PI3K-AKT signaling pathway via ECM (Figure 2). In parallel with our analysis, in a very recent report, THBS2 was confirmed as a novel EMT inducer marker through PI3K-AKT signaling pathway (19). PI3K-AKT is an important signaling pathway activated by TGF-β or via EGF and PDGF receptors. In addition, former studies have widely shown the relationship between this pathway and EMT-related markers (20).

OSMR was another targeted protein that was validated in our experiment. Jiang et al. have reported this gene

![Graph showing relative expression ratio of THBS2, OSMR, and CHI3L1 genes between cancerous and non-cancerous groups.](image)

**Figure 3.** Validation of differentially expressed mRNA in 25 gastric cancer patients. Alteration in the expression of THBS2 (A), OSMR (B) and CHI3L1 (C) genes between cancerous and non-cancerous groups of patients. The genes were normalized by GAPDH as a housekeeping gene. The expressions of these three genes were significantly upregulated (P < 0.05). The data is presented as SEM of three times experiments (***P < 0.01, ****P < 0.001, and *****P < 0.0001).

**Table 4.** Top 10 Significantly Upregulated DEGs in Gastric Cancer

| Gene Name | Ensemble Gene ID | P_adj Value | Log2 Fold Change |
|-----------|-----------------|-------------|-----------------|
| CDH4      | ENSG00000179242 | 1.33E-23    | 6.416           |
| MTHFD1L   | ENSG00000120524 | 2.37E-19    | 2.937           |
| THBS2     | ENSG00000186340 | 1.06E-16    | 4.639           |
| SERPIN1H1 | ENSG0000049257  | 1.63E-11    | 3.06            |
| CHI3L1    | ENSG0000013048  | 5.84E-11    | 11.516          |
| OSMR      | ENSG00000145623 | 1.03E-12    | 4.253           |
| EEF1AP16  | ENSG00000123325 | 2.73E-12    | 2.969           |
| RPS2F21   | ENSG00000100772 | 8.82E-12    | 4.058           |
| NRK       | ENSG00000123572 | 2.22E-11    | 5.427           |
| EEF1AP18  | ENSG00000260557 | 5.74E-11    | 2.982           |
as one of the potential biomarkers for gastric cancer in their integrative microarray analysis (21). Hence, Kucia-Tran et al. have confirmed the overexpression of this gene and its correlation with EMT-related markers in cervical squamous cell carcinoma. They have shown the role of OSM-OSMR in activating the JAK/STAT signaling pathway by JAK2 and STAT3 silencing independently (22). Signal transducer and activator of transcription 3 (STAT3) is an important EMT-inducer that could upregulate the expression of EMT-related markers, especially Snail, Slug, and Twist transcription factors. The aberrant expression of STAT3 has been reported in many cancers, especially in metastatic stages. IL6R/gp130 and OSMR/gp130 could activate STAT3s via JAK2s phosphorylation. JAK/STAT pathway also could be activated via integrins, EGFR-dependent, or independent (23). Smigiel et al. have found a relationship between invasive pancreatic cancer and the upregulation of OSM-OSMR via the JAK/STAT signaling pathway, which leads to cancer stem cell phenotypes formation (24). In the current study, we have observed an overall high expression of this gene in our group of participants with gastric cancer by real-time PCR ($P=0.0016$). However, the expression ratio was variable among patients (Figure 4). In parallel with other studies that we described above, OSMR may induce the JAK/STAT signaling pathway via ECM in cancer cells (Figure 2).

Among 10 high-upregulated candidate genes, CHI3L1 or YKL40 was the last targeted protein involving in ECM, which was validated in Iranian patients. The biological function of this gene is less studied compared with others. However, most studies have identified CHI3L1 as a biomarker for a variety of cancers (13, 25-29) and the high serum level of this glycoprotein is correlated with malignancies (13, 25, 27). Bi et al. have investigated the CHI3L1 expression in 174 Chinese patients with gastric cancer. According to their results, the high expression of CHI3L1 gene is correlated with tumor invasiveness and patient’s short survival rate (28). Similar to Bi et al., this study showed the significant upregulation of CHI3L1 in Iranian patients with gastric cancer ($P=0.0002$). In spite of less information about the exact function of this glycoprotein in cancer cells, the correlation between CHI3L1 gene and EMT-related markers was reported (29). YKL40 has a role in ECM remodeling and might be regulated by STAT3 through the JAK/STAT signaling pathway (14).

As we mentioned above, emphasizing TGF-β, PI3K, and JAK/STAT signaling pathways, signaling mediated by ECM is a key regulator of EMT. The overlapping of different cascades and the expression of EMT-related markers in the response of these activations lead to an alteration in the ECM environment of the surface of cancer cells (30). These findings have supported the importance of ECM components in changing the ECM environment in cancer inva-
sion and progression. Consequently, in parallel with most studies that were discussed above, the results of this study have shown THBS2, OSMR, and CHI3L1 as new candidate biomarkers for gastric cancer in the Iranian population. In line with the present study, the diagnosis of these markers along with other diagnostic markers in gastric cancer can be studied.

4.1. Conclusions

In conclusion, due to the importance of ECM in EMT initiation in cancer cells, we have selected THBS2, OSMR, and CHI3L1 from the top 10 upregulated genes from the large scale analysis of whole transcriptome analysis of gastric cancer raw sample datasets. All selected genes were involved in the EMT procedure via ECM interactions. The expression of these genes has not already been evaluated in the Iranian population. However, there were limitations of sample size; but our results have validated the upregulation of these genes in Iranian patients with gastric cancer. In line with the current study, more extensive research through next generation sequencing and large-scale analysis techniques on Iranian samples can provide a more accurate assessment of gastric cancer malignancy.

Acknowledgments

This study was supported by the Research Institute of Gastroenterology and Liver Diseases of Shahid Beheshti Medical University, Tehran, Iran.

Footnotes

Authors’ Contribution: Lab working and statistical analysis: Shima Abed; supervisor, consulting, experimental adviser: Kaveh Baghaei; consultant: Parviz Pakzad and Mehrdad Hashemi; Adviser: Mohammadreza Zali.

Conflict of Interests: The authors declared no conflict of interest.

Ethical Approval: The ethic committee of Shahid Beheshti University of Medical Sciences approved this study (code of ethics: IR.SBMU.MSP.REC.1395.871.)

Funding/Support: There was no funding for this study.

Patient Consent: Written informed consent was obtained from each individual.

References

1. Pourhoseingholi MA, Vahedi M, Baghestani AR. Burden of gastrointestinal cancer in Asia; an overview. Gastroenterol Hepatol Bed Bench. 2015;8(1):19–27. [PubMed: 25584472]. [PubMed Central: PMC4285928].

2. Elimova E, Shoizaki H, Wadhwa R, Sudo K, Chen Q, Estrella JS, et al. Medical management of gastric cancer: A 2014 update. World J Gastroenterol. 2014;20(38):13637–47. doi: 10.3748/wjg.v20.i38.13637. [PubMed: 25202052]. [PubMed Central: PMC4194548].

3. Tan P, Yeoh KG. Genetics and molecular pathogenesis of gastric adenocarcinoma. Gastroenterology. 2015;149(5):1373–62 e3. doi: 10.1053/j.gastro.2015.05.059. [PubMed: 26073775].

4. Hu B, El Hajj N, Sittler S, Lammert N, Barnes R, Meloni-Ehrg A. Gastric cancer: Classification, histology and application of molecular pathology. J Gastrointest Oncol. 2012;3(3):25–61. doi: 10.3978/j.issn.2078-6891.2012.02.01. [PubMed: 22941016]. [PubMed Central: PMC348539].

5. Huang R, Zong X. Aberrant cancer metabolism in epithelial-mesenchymal transition and cancer metastasis: Mechanisms in cancer progression. Crit Rev Oncol Hematol. 2017;115:11–22. doi: 10.1016/j.critrevonc.2017.04.005. [PubMed: 28602165].

6. Gonzalez DM, Medicci D. Signaling mechanisms of the epithelial-mesenchymal transition. Sci Signal. 2015;8(34):415–26.

7. Zhao S, Fung-Leung WP, Bittrner A, Ngo K, Liu X. Comparison of RNA-seq and microarray in transcriptome profiling of activated T cells. PLoS One. 2014;9(1):e87644. doi: 10.1371/journal.pone.0087644. [PubMed: 24454679]. [PubMed Central: PMC3894192].

8. Wang X, Zhang L, Li H, Sun W, Zhang H, Lai M. THBS2 is a potential prognostic biomarker in colorectal cancer. Sci Rep. 2016;6(33166). doi: 10.1038/srep33166. [PubMed: 27632955]. [PubMed Central: PMC5025892].

9. Slattery ML, Mullany LE, Sakoda LC, Wolff RK, Stevens JR, Samowitz WS, et al. The PI3K/AKT signaling pathway: Associations of miRNAs with dysregulated gene expression in colorectal cancer. Mol Carcinog. 2018;57(2):243–61. doi: 10.1002/mc.22752. [PubMed: 29068474]. [PubMed Central: PMC5760356].

10. Weng TY, Wang CY, Hung YH, Chen WC, Chen YL, Lai MD. Differential expression pattern of THBS1 and THBS2 in lung cancer: Clinical outcome and a systematic-analysis of microarray databases. PLoS One. 2016;11(8):e0161007. doi: 10.1371/journal.pone.0161007. [PubMed: 27513291]. [PubMed Central: PMC4984437].

11. Tiffen PG, Omidvar N, Marquez-Almuna N, Croston D, Watson CJ, Clarkson RW. A dual role for oncostatin M signaling in the differentiation and death of mammary epithelial cells in vivo. J Cell Physiol. 2011;226(4):1072–80. doi: 10.1002/jcp.22563. [PubMed: 21782987]. [PubMed Central: PMC3410889].

12. Caffarel MM, Coleman N. Oncostatin M receptor is a novel therapeutic target in cervical squamous cell carcinoma. J Pathol. 2014;232(2):286–90. doi: 10.1002/path.4305. [PubMed: 24539814]. [PubMed Central: PMC4260121].

13. Itik V, Kemik O, Kemik A, Dulger AC, Sumner A, Soyoral YU, et al. Serum YKL-40 levels in patients with gastric cancer. Biomark Cancer. 2010;2(2):267–77. doi: 10.1002/mc.2008-0097. [PubMed: 18927239]. [PubMed Central: PMC5490408].

14. Caffarel MM, Coleman N. Oncostatin M receptor is a novel therapeutic target in cervical squamous cell carcinoma. J Pathol. 2014;232(2):286–90. doi: 10.1002/path.4305. [PubMed: 24539814]. [PubMed Central: PMC4260121].

15. Singh SK, Bhardwaj R, Wilczynska KM, Dumm CR, Kordula T. A complex of nuclear factor I-X3 and STAT3 regulates astrocyte and glioma migration through the secreted glycoprotein YKL-40. J Biol Chem. 2011;286(45):39893–901. doi: 10.1074/jbc.M111.257451. [PubMed: 21951459]. [PubMed Central: PMC3220556].

16. Sun R, Wu J, Chen Y, Lu M, Zhang S, Lu D, et al. Down regulation of Thrombospondin2 predicts poor prognosis in patients with gastric cancer. Mol Cancer. 2014;13:225. doi: 10.1186/1476-4598-13-225. [PubMed: 25262009]. [PubMed Central: PMC418990].

17. Zhuo C, Li X, Zhuang H, Tian S, Cui H, Jiang R, et al. Elevated THBS2, COL1A2, and SPH expression levels as predictors of gastric cancer prognosis. Cell Physiol Biochem. 2016;40(6):216–24. doi: 10.1055/s-0036-1578884. [PubMed: 27997896].

18. Kim J, Bamlet WR, Oberig AE, Chaffee KG, Donahue G, Cao XJ, et al. Detection of early pancreatic ductal adenocarcinoma with thrombospondin-2 and CA9-9 blood markers. Sci Transl Med. 2017;9(398), doi: 10.1126/scitranslmed.aah5583. [PubMed: 2870476]. [PubMed Central: PMC5727893].

Abed S et al.
18. Jiang B, Li S, Jiang Z, Shao P. Gastric cancer associated genes identified by an integrative analysis of gene expression data. Biomed Res Int. 2017;2017:7259097. doi: 10.1155/2017/7259097. [PubMed: 28222943]. [PubMed Central: PMC5292384].
19. Liu QH, Ma LS. Knockdown of thrombospondin 2 inhibits metastasis through modulation of PI3K signaling pathway in uveal melanoma cell line M23. Eur Rev Med Pharmacol Sci. 2018;22(19):6230-8. doi: 10.26355/eurrev_201810_16029. [PubMed: 30338765].
20. Xu W, Yang Z, Lu N. A new role for the PI3K/Akt signaling pathway in the epithelial-mesenchymal transition. Cell Adh Migr. 2015;9(4):317-24. doi: 10.1080/19336918.2015.1016686. [PubMed: 26241004]. [PubMed Central: PMC4594353].
21. Junnila S, Kokkola A, Karjalainen-Lindsberg ML, Puolakkainen P, Monni O. Genome-wide gene copy number and expression analysis of primary gastric tumors and gastric cancer cell lines. BMC Cancer. 2010;10:73. doi: 10.1186/1471-2407-10-73. [PubMed: 20187983]. [PubMed Central: PMC2837868].
22. Kucia-Tran JA, Tulikki V, Smith S, Scarpini CG, Hughes K, Araujo AM, et al. Overexpression of the oncostatin-M receptor in cervical squamous cell carcinoma is associated with epithelial-mesenchymal transition and poor overall survival. Br J Cancer. 2016;115(2):212-22. doi: 10.1038/bjc.2016.199. [PubMed: 27351213]. [PubMed Central: PMC4947707].
23. Wendt MK, Balanis N, Carlin CR, Schiemann WP. STAT3 and epithelial-mesenchymal transitions in carcinomas. JASSTAT. 2014;3(1):e28975. doi: 10.4161/jkst.28975. [PubMed: 24843831]. [PubMed Central: PMC4024059].
24. Smigel M, Parameswaran N, Jackson MW. Potent EMT and CSC phenotypes are induced by oncostatin-M in pancreatic cancer. Mol Cancer Res. 2017;15(4):478-88. doi: 10.1158/1541-7786.MCR-16-0337. [PubMed: 28051127]. [PubMed Central: PMC5380554].
25. Wang D, Zhai B, Hu F, Liu C, Zhao J, Xu J. High YKL-40 serum concentration is correlated with prognosis of Chinese patients with breast cancer. PloS One. 2012;7(12). e50127. doi: 10.1371/journal.pone.0051127. [PubMed: 23227243]. [PubMed Central: PMC3515550].
26. Reckles AD, White C, Ling H. The chitinase 3-like protein human cartilage glycoprotein 39 (HC-gp39) stimulates proliferation of human connective-tissue cells and activates both extracellular signal-regulated kinase- and protein kinase B-mediated signalling pathways. Biochem J. 2002;365(Pt 1):119-26. doi: 10.1042/BJ20020075. [PubMed: 12071845]. [PubMed Central: PMC1222662].
27. Allin KH, Bojesen SE, Johansen JS, Nordestgaard BG. Cancer risk by combined levels of YKL-40 and C-reactive protein in the general population. Br J Cancer. 2012;106(1):399-205. doi: 10.1038/bjc.2011.501. [PubMed: 22095223]. [PubMed Central: PMC3251851].
28. Bi J, Lau SH, Lv ZL, Xie D, Li W, Lai YR, et al. Overexpression of YKL-40 is an independent prognostic marker in gastric cancer. Hum Pathol. 2009;40(12):1790-7. doi: 10.1016/j.humpath.2009.07.005. [PubMed: 19765801].
29. Jefri M, Huang YN, Huang WC, Tai CS, Chen WL. YKL-40 regulated epithelial-mesenchymal transition and migration/invasion enhancement in non-small cell lung cancer. BMC Cancer. 2015;15:390. doi: 10.1186/s12885-015-1592-3. [PubMed: 26275425]. [PubMed Central: PMC4537570].
30. Du L, Tang JH, Huang GH, Xiang Y, Lv SQ. The progression of epithelial-mesenchymal transformation in gliomas. Chinese Neurosurg J. 2017;3(1):3-7. doi: 10.1186/s41016-017-0086-3.